sermorelin + GHRP-2
updated
Sermorelin + GHRP-2 is a blend of two growth-hormone releasers: a growth-hormone-releasing hormone fragment and a ghrelin-receptor peptide. It is used hoping for fat loss, muscle, sleep and recovery, on the idea of synergy. In one intravenous experiment in eight healthy men, the pair released more growth hormone than either alone but no more than their summed responses; no study tested a mixed vial, repeated injections or those outcomes. Graded D for the gap between one acute hormone test and any clinical benefit; FDA has raised impurity and immune-reaction concerns about GHRP-2.
GHRH(1-29) amide + GHRP-2
- GHRH(1-29) amide + GHRP-2
- Acute intravenous evidence differs from repeated subcutaneous use
Which combination was actually tested?
The experiment used GHRH(1-29) amide and GHRP-2 as intravenous challenges. It did not test a commercial mixed vial, repeated subcutaneous dosing or a third peptide.
source: Eight-man crossover · acute GH release, Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
Has this exact combination been tested?
The eight-man intravenous experiment tested the two ingredients together. A separate retrospective report used three secretagogues. Neither studied repeated subcutaneous use of the two-ingredient blend.
source: Evidence for the exact combination, PubMed.
Did the combination produce synergy?
The combined GH response exceeded either separate response, but was not significantly greater than their sum. The study therefore did not demonstrate synergy.
Why distinguish a larger response from synergy?
A combination can produce more than either ingredient alone while remaining additive. Calling any larger response synergy overstates what the comparison established.
Does that show muscle gain or improved sleep?
No. Those outcomes were not tested. A hormone challenge measures a short response to administered substances; it cannot establish a benefit from months of use.
Does the testosterone-clinic report settle the question?
No. That retrospective report used three secretagogues alongside testosterone, rather than this two-ingredient intervention alone. Its hormone measurements cannot isolate the effect of sermorelin plus GHRP-2.
source: Retrospective series · a different three-drug regimen, Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels, 2017. PMID 28830317.
What is known about repeated-use safety?
The acute experiment does not establish it. FDA’s GHRP-2 assessment raises impurity and immune-reaction concerns and describes serious events in recipients, with causality not established. Safety during repeated subcutaneous use of this blend remains unestablished.
source: FDA · ingredient safety concerns, FDA · ingredient safety concerns
Does the IV study supply a subcutaneous ratio or cycle?
No. The route, exposure and duration differ. The study parameters describe the experiment; they do not establish a repeated-use protocol for a finished blend.
Studies and sources
Eight-man crossover · acute GH release
Acute randomized crossover study
Tiulpakov AN et al. Clinical Endocrinology, 1995. PMID 7586605.
Eight healthy men received intravenous GHRH(1-29) amide, GHRP-2 and their combination in randomized order. The combination increased GH exposure, but did not significantly exceed the sum of the separate responses. No long-term body-composition or functional outcome was tested.
Read the original sourceRetrospective series · a different three-drug regimen
Retrospective human series
Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels, 2017. PMID 28830317.
Fourteen selected men receiving testosterone also used sermorelin, GHRP-2 and GHRP-6. The report evaluated IGF-1. Its added GHRP-6, concurrent testosterone and retrospective design prevent attribution to the two-ingredient sermorelin/GHRP-2 blend.
Read the original sourceFDA · ingredient safety concerns
Regulatory safety assessment
FDA · ingredient safety concerns
FDA identifies peptide-impurity and immune-reaction concerns with GHRP-2. It reports serious events in recipients, including increased insulin requirements, infection, pancreatitis and deaths in critically ill subjects, while stating that causality has not been established. These reports do not quantify the risk of repeated subcutaneous sermorelin/GHRP-2.
Read the original sourceEvidence for the exact combination
Combination evidence
PubMed.
The eight-man intravenous experiment tested the two ingredients together. A separate retrospective report used three secretagogues. Neither studied repeated subcutaneous use of the two-ingredient blend.
Why is sermorelin + GHRP-2 in D tier?
D reflects the gap between an acute hormone-response experiment and demonstrated clinical benefit. The eight-man study did not establish improved sleep, body composition or recovery from repeated use.
how tiers are graded: methodology · every cited source · about reptides.
Research reference, not medical advice. Entries distinguish product labels, study doses and reported protocols. Check the linked source for the product, route and population.